AK-FLUOR 10%
LOE Approachingfluorescein
NDAINTRAVENOUSINJECTABLE
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
AK-FLUOR 10% (fluorescein) is 465 to 490 nm and fluoresces, i. Approved for retinopathy, diabetic retinopathy, retinal vein occlusion and 3 more indications. First approved in 2008.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AK-FLUOR 10% is an intravenous injectable fluorescein diagnostic agent used to visualize retinal and choroidal vasculature during fundus imaging. The dye is excited by blue light (465-490 nm) and emits yellowish-green fluorescence (520-530 nm), allowing clinicians to demarcate blood vessel abnormalities in retinopathy, diabetic retinopathy, retinal vein occlusion, macular edema, and macular degeneration. It is a diagnostic tool rather than a therapeutic agent, enabling visualization of disease without direct treatment.
LOE Approaching
Diagnostic agent approaching loss of exclusivity with minimal direct revenue data; team likely smaller and focused on margin protection rather than growth.
Mechanism of Action
465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be…
Indications (6)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.